Lancet Publishes First Trial To Show Overall Survival Benefit Of Halaven® (eribulin) in People With Soft Tissue Sarcoma Sub-Types - Seite 4
Media Enquiries
Eisai
Cressida Robson / Ben Speller
+44(0)7908 314 155 / +44(0) 7951 078 795
Cressida_Robson@eisai.net
Ben_Speller@eisai.net
Media Enquiries
Tonic Life Communications
Alex Davies / Emma Coughlan
+44 (0)7720 496 472 / +44(0) 7772 534 646
Alex.Davies@toniclc.com
Emma.Coughlan@toniclc.com